title: A highly curable lymphoma occurs preferentially in the proximal tibia of young patients.
abstract: The presentation of two 19-year-old male subjects with stage I non-Hodgkin lymphoma in the proximal tibia prompted an extensive review of institutional and national databases to assess whether there is any statistical evidence that these reflected a previously overlooked syndromic pattern of presentation. The institutional records of a single institution were reviewed for presentation of non-Hodgkin lymphoma in the bone. The records of two additional institutions were reviewed for all reports of non-Hodgkin lymphoma in the tibia. Analysis was performed on data from Surveillance, Epidemiology, and End Results (SEER) dichotomized to bone presentation in the lower extremity versus other bones. Institutional databases included 20 patients with tibial presentation of lymphoma with a median age of 22.5 years (versus 42 for all bone lymphomas; P<0.001). Eighteen out of twenty patients had diffuse large B-cell lymphoma, and all patients aged ≤40 achieved remission and apparent cure. Distinctive and unusual features were a tendency for bilateral involvement of the tibia and sclerotic changes on X-ray. SEER data included 808 cases of bone lymphoma; the fraction of cases presenting in the lower extremity versus other bone sites is higher at ages ≤40 years (38% versus 19%; P<0.0001). Presentation in the lower extremity, as compared with other bone sites, confers 97% overall survival in patients aged ≤40 (versus 82%; P=0.01). This survival effect was independent of stage. In contrast, no significant difference in overall survival was identified for lower extremity versus non-lower extremity site for age >40. These data show a previously undescribed syndromic pattern of disease presentation: bone lymphoma in young patients is likely to present in the lower extremity-specifically the proximal tibia-has atypical sclerotic features on X-ray, is often bilateral, and has an excellent prognosis compared with bone lymphomas at other sites matched for stage and age.
authors.forename: M Kristina
authors.initials: MK
authors.lastname: Subik
authors.forename: Megan
authors.initials: M
authors.lastname: Herr
authors.forename: Robert E
authors.initials: RE
authors.lastname: Hutchison
authors.forename: Jennifer
authors.initials: J
authors.lastname: Kelly
authors.forename: Wakenda
authors.initials: W
authors.lastname: Tyler
authors.forename: Mihai
authors.initials: M
authors.lastname: Merzianu
authors.forename: W Richard
authors.initials: WR
authors.lastname: Burack
mesh_terms: D000293:Adolescent; D000328:Adult; D017677:Age Distribution; D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D018951:Antigens, CD20 / Q000032:analysis; D014408:Biomarkers, Tumor / Q000032:analysis; D001706:Biopsy; D001859:Bone Neoplasms / Q000737:chemistry / Q000401:mortality / Q000473:pathology* / Q000628:therapy; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D007223:Infant; D007231:Infant, Newborn; D053208:Kaplan-Meier Estimate; D008223:Lymphoma / Q000737:chemistry / Q000401:mortality / Q000473:pathology* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011859:Radiography; D012074:Remission Induction; D012307:Risk Factors; D018426:SEER Program; D013977:Tibia / Q000737:chemistry / Q000000981:diagnostic imaging / Q000473:pathology*; D016896:Treatment Outcome; D014481:United States / Q000453:epidemiology; D055815:Young Adult
chemical_list: D018951:Antigens, CD20; D014408:Biomarkers, Tumor
references.citation: Med Pediatr Oncol. 1991;19(1):22-7
references.pmid: 1990254
references.citation: J BUON. 2003 Apr-Jun;8(2):163-6
references.pmid: 17472245
references.citation: J Clin Oncol. 1986 Apr;4(4):496-501
references.pmid: 3958763
references.citation: J Clin Oncol. 1989 Sep;7(9):1275-80
references.pmid: 2769328
references.citation: J Clin Oncol. 1999 Feb;17(2):456-9
references.pmid: 10080585
references.citation: Cancer. 1986 Dec 15;58(12):2646-55
references.pmid: 3779614
references.citation: J Clin Oncol. 2003 Jun 15;21(12):2232-3
references.pmid: 12805320
references.citation: Am J Clin Pathol. 2007 Jan;127(1):47-54
references.pmid: 17145622
references.citation: Clin Nucl Med. 2005 May;30(5):353-5
references.pmid: 15827414
references.citation: Am J Surg Pathol. 2005 Jun;29(6):832-6
references.pmid: 15897752
references.citation: J Bone Joint Surg Am. 2006 Mar;88(3):583-94
references.pmid: 16510826
references.citation: Am J Hematol. 2012 Sep;87(9):924-5
references.pmid: 22641233
references.citation: Ann Oncol. 2007 Jan;18(1):129-135
references.pmid: 17018705
references.citation: Med Pediatr Oncol. 1992;20(6):506-13
references.pmid: 1435521
references.citation: Curr Probl Diagn Radiol. 2009 Sep-Oct;38(5):228-36
references.pmid: 19632500
references.citation: J Clin Oncol. 2002 May 1;20(9):2293-301
references.pmid: 11981000
references.citation: Am J Surg Pathol. 2009 Oct;33(10):1463-9
references.pmid: 19675454
references.citation: Cancer. 2006 Jun 15;106(12):2652-6
references.pmid: 16700039
references.citation: Cancer. 1987 Jan 15;59(2):335-9
references.pmid: 3802019
references.citation: Leuk Lymphoma. 2010 Jan;51(1):39-49
references.pmid: 19860629
references.citation: Int J Radiat Oncol Biol Phys. 2004 Jul 1;59(3):760-4
references.pmid: 15183479
references.citation: Int J Surg Pathol. 2002 Oct;10(4):257-66
references.pmid: 12490975
references.citation: Am J Surg Pathol. 2003 Sep;27(9):1269-77
references.pmid: 12960812
references.citation: Am J Clin Pathol. 2008 May;129(5):723-6
references.pmid: 18426731